Development of an in-body cell therapy treatment using nanoparticles

使用纳米粒子开发体内细胞疗法

• 批准号: 10026818
• 金额: $ 67.7万
• 依托单位: IMMTUNE THERAPIES LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10026818
• 关键词: Development; body; cell; therapy; treatment

ImmTune Therapies is developing a revolutionary new method of immune cell therapy, whereby patients' cells can be genetically modified inside their bodies to endow them with cancer-fighting properties. Our first focus is in CD19 Chimeric Antigen Receptor (CAR) T-cell therapy, a game-changing cancer treatment where patient's immune cells are modified to express a CAR, which directs them towards a molecule named CD19, which is expressed on cancer cells in many types of B-cell lymphoma. Our product is a targeted nanoparticle gene-delivery technology, called NanoCART-19, designed to deliver CARs to T-cells in the body.Our groundbreaking method will offer major advantages over current and developing CAR-T technologies, which rely on manufacturing the CAR-T cells outside the body. The currently approved process causes the treatments to cost \>£250,000pp and take 6-8 weeks to reach patients, which renders over 75% of NHS patients in need ineligible to receive therapy. With our method, treatment can become as quick as a **one-step off-the-shelf injection**, and **5-10 fold cheaper**, allowing treatment of **many more patients** and **lowering the burden** on healthcare systems such as the NHS.Our **rigorous customer discovery** (over a 12-month period) has highlighted the significant market desire for such a technology, from **pharmaceutical to medical professionals**. However, a robust demonstration of the capability of our technology is needed to secure investment and accelerate development.This project will demonstrate the potential of NanoCART-19 in treating B-cell lymphomas, by experimental validation in preclinical models and will compare CAR-T cells generated by NanoCART-19, to those currently used in the clinic. We will also build a supporting case to take this innovative method of cell therapy into humans for the first time, by engaging with regulatory bodies, investigating manufacturing scale-up and GMP compliance and working to position NanoCART-19 in the rapidly developing CAR-T market.ImmTune has gathered an **expert team** to deliver this ambitious project, including the **Cell and Gene Therapy Catapult** and **Dr Robert Koechl from King's College London**. The successful completion of this collaboration will drive ImmTune's product **towards the clinic and stimulate growth and investment,** allowing CAR-T therapy to benefit more patients in urgent need.Today, we are closer than ever to creating cancer treatments that don't just treat patients but can actually cure them, in a single treatment. ImmTune's technology is designed to make these cures available to many more patients who need them, **democratising cell therapy and opening new markets**.

ImmTune Therapies正在开发一种革命性的免疫细胞治疗新方法，通过这种方法，患者的细胞可以在体内进行遗传修饰，使其具有抗癌特性。我们的第一个重点是CD 19嵌合抗原受体（CAR）T细胞疗法，这是一种改变游戏规则的癌症治疗方法，患者的免疫细胞被修饰为表达CAR，将其导向一种名为CD 19的分子，该分子在许多类型的B细胞淋巴瘤的癌细胞上表达。我们的产品是一种靶向纳米颗粒基因递送技术，称为NanoCART-19，旨在将汽车递送到体内的T细胞。我们的开创性方法将提供比当前和正在开发的CAR-T技术更大的优势，这些技术依赖于在体外制造CAR-T细胞。目前批准的过程导致治疗费用超过250，000英镑，需要6-8周才能到达患者，这使得超过75%的NHS患者没有资格接受治疗。通过我们的方法，治疗可以变得像 ** 一步现成的注射 ** 一样快速，并且 ** 便宜5-10倍 **，允许治疗 ** 更多的患者 ** 并 ** 减轻NHS等医疗保健系统的负担 **。我们 ** 严格的客户发现 **（超过12个月的时间）凸显了从 ** 制药到医疗专业人员 ** 对这种技术的巨大市场需求。然而，我们需要对我们的技术能力进行强有力的证明，以确保投资和加速开发。该项目将通过临床前模型的实验验证来证明NanoCART-19在治疗B细胞淋巴瘤方面的潜力，并将NanoCART-19产生的CAR-T细胞与目前临床上使用的CAR-T细胞进行比较。我们还将建立一个支持案例，通过与监管机构合作，调查生产规模和GMP合规性，并致力于在快速发展的CAR-T市场中定位NanoCART-19，首次将这种创新的细胞治疗方法应用于人类。ImmTune已经聚集了一个 ** 专家团队 ** 来交付这个雄心勃勃的项目，包括 ** 细胞和基因治疗弹射器 ** 和 ** 来自伦敦大学国王学院的罗伯特·科赫尔博士 **。此次合作的成功完成将推动ImmTune的产品 ** 走向临床，并刺激增长和投资，** 让CAR-T疗法惠及更多急需的患者。今天，我们比以往任何时候都更接近于创造出不仅能治疗患者，而且能在单一治疗中治愈患者的癌症治疗方法。ImmTune的技术旨在使更多需要这些治疗的患者获得这些治疗，** 使细胞疗法民主化并开辟新市场 **。